CD8A and neoplasm: To address this issue, some ex vivo generated DCs-based vaccines are directly administered intranodally, as for the CD1c+ DCs pulsed with HLA-A2.1-restricted tumor peptides administered to patients with stage IV melanoma (NCT01690377), which generated tumor-specific CD8+ T cells responses and further improvement of survival (173).